Figure 5 shows that BDCA-1+/BDCA-3+ myDC co-cultured with T-VEC-treated 938-mel cells indeed induce IFN-γ secretion from both the NY-ESO-1 TCR transfected T cells as well as from the gp100 TCR transfected T cells. The effect was highest using a DC:tumor cell ratio of 1:5, although it remained lower than DC pulsed with 10 nM peptide. Thus, BDCA-1+/BDCA-3+ myDC that have taken up T-VEC-treated dying tumor cells are capable of cross-presenting tumor antigens to tumor-specific T cells. The gene discussed is PMEL; the disease is neoplasm.